Longevity.Technology
Longevity news and interviews, DLT biotech intelligence for company teams, clinic discovery, and partnership routes for sponsors and advertisers.
- Open access
- News + podcast
- Professional data
- DLT demo-led
- Paid reports
- From $29.99
- Legal operator
- First Longevity Ltd
Who they are
Overview
Longevity.Technology is the trading name of First Longevity Ltd, a UK company incorporated in 2019. Its free side covers daily longevity news, interviews, the UNLOCKED podcast and a clinic directory. Its professional product is DLT, a demo-led data platform that tracks longevity biotech companies and assets; it is quoted for biotech and pharma teams and, per its pricing page, is not offered to investors. Clinics can register for the directory, and sponsors and advertisers work with the team through inquiry.
At a glance
- Legal operator
- First Longevity Ltd
- Active UK private company 12345643; the public brand is Longevity.Technology.
- Open access
- Longevity.Technology news + daily briefing · UNLOCKED podcastLongevity.Technology news + daily briefingUNLOCKED podcast
- Current articles, the daily email briefing and UNLOCKED episodes are available through the public site.
- Professional products
- DLT + bespoke intelligenceDLTbespoke intelligence
- Sales-led. Biotech teams are quoted annual or quarterly named-seat subscriptions and large pharma custom terms; DLT is not available to investors.
- Published paid products
- 2023 report · first-half 2024 report · research subscription2023 reportfirst-half 2024 reportresearch subscription
- Older research products sold separately from DLT; confirm current availability and price on each purchase page.
- Clinic pathway
- Clinic discovery + free registrationfree registration
- The directory serves people researching clinics and organizations seeking listing visibility.
- Latest verified event
- The Longevity Show · June 2026
- The first edition has concluded; no future ticketed edition was confirmed in this review.
- Open access
- News + podcast
- Professional data
- DLT demo-led
- Paid reports
- From $29.99
- Founded
- First Longevity Ltd · incorporated 2019
- Footprint
- Editorial, data, research, clinics, podcast and events
- Consumer footprint
- For readers, investors, operators, clinics, sponsors and sector participants
- Published prices
- Free access · reports from $29.99 · DLT by demo
Company claims
Understanding the longevity sector
Longevity.Technology presents its media as a resource for professionals, innovators and investors exploring the science, technology and business of longevity.
Searchable longevity intelligence
Longevity.Technology says its DLT data platform brings company information, signals and trends from across longevity into one searchable dataset.
Access and commercial model
Published prices and inquiry routes
Paid reports
News and podcast access are free; DLT and commercial services use direct inquiry.
DLT is the current intelligence platform; the separately sold investment reports cover 2023 and the first half of 2024.
Daily briefing
Public reading and newsletter signup are available from the editorial site.
FreeRead news and join the daily briefingClinic registration
Ask how listings are reviewed, ranked, updated and connected to inquiries before relying on the channel.
FreeReview clinic registrationUNLOCKED
Episodes are publicly accessible from the podcast page and linked listening platforms.
FreeExplore UNLOCKEDFirst-half 2024 report
Verify that the historical coverage period matches the decision you are making now.
$29.99View the first-half 2024 report2023 annual report
A historical report sold separately from DLT and current custom research.
$59.99View the 2023 annual reportDLT platform
Biotech teams: pricing on request for an annual or quarterly named-seat subscription. Large pharma: custom terms. Not available to investors. Ask for seats, datasets, export rights, onboarding and support in one proposal.
Quoted by tierExplore DLT intelligenceBespoke intelligence
Define the research question, source coverage, method, named deliverables, review cycle and reuse rights.
Custom quoteReview bespoke intelligenceResearch subscription
An older investment-research subscription sold separately from DLT. Its purchase page could not be rechecked on 26 September 2026; confirm the current price and checkout there before buying.
Legacy product · price to confirmReview research subscriptionAdvertising and sponsorship
Request the audience definition, placement, duration, labeling, reporting and cancellation terms for the proposed campaign.
EnquiryReview advertising and sponsorship
- Current versus legacy
DLT is the current intelligence platform. The 2023 and 2024 reports and their investment subscription are older products with separate access terms.
- DLT eligibility
The DLT pricing page says the platform is not available to investors. Investor readers can still use the free news and podcast and the separately sold reports.
- Event access
The June 2026 Longevity Show has concluded, so its former ticket route is not presented as a current purchase option.
First-party product, report, registration, podcast and advertising pages checked 30 August 2026; DLT pricing and eligibility rechecked 25–26 September 2026.
Daily briefing
Choose the right part of the ecosystem
Each card leads to the first-party page for that exact publication, product or commercial route.
Publishing, clinics and commercial participation
These routes cover free audience products and inquiry-led visibility services.
Daily news and briefing
Publication + email briefing
Daily longevity articles, interviews, analysis and an email briefing from the editorial site.
Availability: available
Link verified
Clinic registration
Publishing, clinics and commercial participation
These routes cover free audience products and inquiry-led visibility services.
Longevity Clinics directory registration
Clinic visibility service
Free registration · A registration route for clinics seeking inclusion and prospective inquiries from the directory.
Availability: available
Link verified
UNLOCKED
Publishing, clinics and commercial participation
These routes cover free audience products and inquiry-led visibility services.
UNLOCKED podcast
Interview and news program
Interviews and news roundups with founders, scientists, clinicians, investors and other sector participants.
Availability: available
Link verified
First-half 2024 report
Intelligence and paid research
DLT is the current professional intelligence product. The investment subscription and reports are older, separately priced research products and do not establish DLT access.
First-half 2024 investment report
Paid research report
An individually priced report retained on the investment portal.
Availability: available
Link verified
2023 annual report
Intelligence and paid research
DLT is the current professional intelligence product. The investment subscription and reports are older, separately priced research products and do not establish DLT access.
2023 annual investment report
Paid research report
An individually priced annual report retained on the investment portal.
Availability: available
Link verified
DLT platform
Intelligence and paid research
DLT is the current professional intelligence product. The investment subscription and reports are older, separately priced research products and do not establish DLT access.
DLT intelligence platform
Professional data platform
Demo · quoted by tier · Company and asset search, dashboards, alerts, watchlists, exports, reports and a structured-data copilot for longevity biotech research.
Availability: available
Link verified
Bespoke intelligence
Intelligence and paid research
DLT is the current professional intelligence product. The investment subscription and reports are older, separately priced research products and do not establish DLT access.
Bespoke intelligence
Custom research service
Custom reports built from DLT's specialist dataset and domain research for questions that need deeper analysis.
Availability: available
Link verified
Research subscription
Intelligence and paid research
DLT is the current professional intelligence product. The investment subscription and reports are older, separately priced research products and do not establish DLT access.
Research subscription
Legacy investment access
Price to confirm · An older investment-research subscription, separate from DLT. Confirm the current price and checkout on its purchase page before buying.
Availability: available
Link verified
Advertising and sponsorship
Publishing, clinics and commercial participation
These routes cover free audience products and inquiry-led visibility services.
Advertising and sponsorship
Commercial media service
Campaign, sponsorship and ecosystem visibility options; the reviewed page did not display a rate card.
Availability: available
Link verified
- DLT intelligence platformContact for pricing
For professionals
Company and asset search, dashboards, alerts, watchlists, exports, reports and a structured-data copilot for longevity biotech research. · Demo · price on request · DLT platform: Price on request
Explore DLT intelligenceLink verifiedAppSoftware
- Bespoke intelligenceContact for pricing
For professionals
Define the research question, source coverage, method, named deliverables, review cycle and reuse rights. · Custom quote
Review bespoke intelligenceLink verifiedServiceProfessional Service
- Daily news and briefingFree
For consumers
Daily longevity articles, interviews, analysis and an email briefing from the editorial site. · Free · Daily briefing: Free
Read news and join the daily briefingLink verifiedServiceSubscription
- Research subscription$15 · per monthPublished price · Price verified 2026-08-30
For professionals
$99 introductory annual access renewing at $150 was also displayed on the reviewed page. · $1 intro / $15 renewal monthly
Review research subscription pricingLink verifiedServiceSubscription
- First-half 2024 investment report$29.99Published price · Price verified 2026-08-30
For professionals
An individually priced report retained on the investment portal. · First-half 2024 report: $29.99
View the first-half 2024 reportLink verifiedServiceReport
- 2023 annual investment report$59.99Published price · Price verified 2026-08-30
For professionals
An individually priced annual report retained on the investment portal. · 2023 annual report: $59.99
View the 2023 annual reportLink verifiedServiceReport
- Clinic registrationFree
For professionals
Ask how listings are reviewed, ranked, updated and connected to inquiries before relying on the channel. · Free · Longevity Clinics directory registration: Free registration
Review clinic registrationLink verifiedServiceProfessional Service
- UNLOCKED podcastFree
For consumers
Interviews and news roundups with founders, scientists, clinicians, investors and other sector participants. · Free · UNLOCKED: Free
Explore UNLOCKEDLink verifiedServiceSubscription
- Advertising and sponsorshipContact for pricing
For professionals
Request the audience definition, placement, duration, labeling, reporting and cancellation terms for the proposed campaign. · Enquiry
Review advertising and sponsorshipLink verifiedServiceProfessional Service
What each program delivers
Publishing, intelligence and participation
Longevity.Technology publishes news and interviews alongside research products, a data platform, directories and events.
Articles + newsletter
Editorial publishing
Daily news, interviews, analysis and email distribution cover science, companies, clinics, products, investment and policy.
Companies + assets
DLT market intelligence
Longevity.Technology reports coverage of 728 biotech companies, 3,176 aging-disease assets and 1,585 gerotherapeutic assets, with continuous signal monitoring. It describes a review workflow using AI, validators and human reviewers.
Reports + custom briefs
Commercial research
Historical reports remain available individually, while DLT promotes generated briefs, market maps, diligence output and bespoke intelligence.
Listings + inquiries
Longevity Clinics directory
The public directory presents clinic profiles and prices, while a separate registration route invites clinics to seek inclusion and inquiries.
Interviews + gatherings
UNLOCKED and events
The podcast publishes public interviews and news roundups. The first Longevity Show brought attendees, speakers, exhibitors and sponsors together in London in June 2026.
Who can access what
Access by program
Public content is open; professional products and commercial participation use product-specific purchase, registration or inquiry routes.
- Editorial
- Read current articles or join the daily email briefing from the main site.
- DLT
- Biotech and pharma teams can book a demo and request a quote; the platform is not available to investors.
- Reports
- 2023 report + first-half 2024 report2023 reportfirst-half 2024 report
- Both historical investment reports remain individually priced.
- Clinic directory
- Clinics can submit the first-party registration route for review.
- Advertising + sponsorship
- Scope, inventory, audience and rates are confirmed directly.
Ownership and public leadership
Who operates the organization
First-party leadership names align with the current statutory director record for First Longevity Ltd.
Founder and chief executive officer
Phil Newman
Current director and person with significant control, holding more than 50% but less than 75% of shares and voting rights.
Non-executive chair
George Sutherland
Named on the organization site and recorded as a current First Longevity Ltd director.
Non-executive director
Tom Britton
Named on the organization site and recorded as a current First Longevity Ltd director.
Advertising contact
Dev Heaton
Named on the current advertising page for commercial inquiries.
Clinics initiative
Manjit Sareen
Named in first-party material for the clinic-directory program.
UNLOCKED co-host
Dr Nina Patrick
Named on the podcast page; this program role is not presented as a company-director position.
What can be checked
Product and procurement record
A newsroom and a professional data platform run by the same UK operator, with DLT sold to biotech and pharma teams rather than investors.
What sets it apart
Biotech data built for company teams: DLT reports coverage of 728 biotech companies, 3,176 aging-disease assets and 1,585 gerotherapeutic assets, with search, alerts, exports and a structured-data copilot.
Newsroom and data under one operator: daily reporting, the UNLOCKED podcast and a clinic directory run alongside DLT, all from First Longevity Ltd since 2019. Companies House names Phil Newman as the person with significant control.
An industry source for major outlets: The Wall Street Journal, The New York Times, Bloomberg and Fortune have cited Longevity.Technology or Phil Newman in their longevity coverage.
Confirm before buying
DLT is quoted per team: biotech buyers choose an annual or quarterly named-seat subscription, and large pharma buyers receive custom terms. The platform is not available to investors.
The older research subscription could not be rechecked on 26 September 2026; confirm its current price and checkout before buying.
The paid investment reports cover 2023 and the first half of 2024; check that the period fits the decision you are making.
Reporting and company history
Press and announcements
Mainstream coverage establishes the organization's visibility as an industry source. Company announcements are listed separately because they document what First Longevity said and when.
Independent coverage and industry citations
Most major-outlet items use Longevity.Technology or Phil Newman as a source within broader reporting rather than reviewing the company or DLT directly.
Forbes
Contributor interview
29 Jun 2022
The New York Times
Industry-data citation
19 Jul 2022
The Wall Street Journal
Industry context
11 Jul 2023
Fortune
Industry commentary
9 Sep 2024
Business Insider
Market citation
11 Oct 2024
The Wall Street Journal
Industry context
23 Mar 2025
The New York Times Magazine
Topic-reporting citation
9 May 2026
Bloomberg
Industry source context
14 May 2026
The Wall Street Journal
Industry source context
1 Jun 2026
First-party announcements
These items establish company statements and launches, not independent validation of product performance or partnership impact.
Longevity.Technology
Company announcement
6 Aug 2020
Longevity.Technology
Company announcement
13 Aug 2025
Longevity.Technology
Event announcement
2026 event cycle
Longevity.Technology
Product announcement
12 Feb 2026
Longevity.Technology
Company announcement
18 Mar 2026
Longevity.Technology
Company announcement
5 May 2026
Common questions
Frequently asked questions
Transparency
Transparency and sources
Researched by Longevity.io
- Reviewed
Identity, ownership and leadership
- Company record
- Director record
- Ownership record
- Data controller record
- Company information
Programs, products and prices
- Editorial site
- Data product
- Product detail
- Pricing and eligibility
- Paid research
- Paid report
- Paid report
- Clinic participation
- Podcast
- Commercial services
Events and company announcements
- Official event site
- Event announcement
- Company announcement
- Company announcement
- Product announcement
- Company announcement
- Company announcement
Terms and privacy
- Site terms
- Privacy
Independent reporting and industry context
- Contributor interview
- Industry-data citation
- Industry context
- Industry commentary
- Market citation
- Industry context
- Topic reporting
- Industry source context
- Industry source context
Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.
Keep exploring
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint